Research Article

The Combination of Seven Preoperative Markers for Predicting Patients with Gastric Cancer to Be Either Stage IV or Non-Stage IV

Wei Ge, Li-ming Zheng, and Gang Chen

Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu Province 210008, China

Correspondence should be addressed to Gang Chen; 331812195@qq.com

Received 14 February 2018; Revised 9 May 2018; Accepted 16 May 2018; Published 3 June 2018

Academic Editor: Haruhiko Sugimura

Copyright © 2018 Wei Ge et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

To assess whether preoperative markers could predict the stage of patients with gastric cancer. We analyzed retrospectively the preoperative indicators between stage IV and non-stage IV gastric cancer at the Gastrointestinal Surgery of Nanjing Drum Tower Hospital. A total of 500 patients with gastric cancer were screened. Of all the variables, alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125, carbohydrate antigen (CA) 199, carbohydrate antigen (CA) 724, carbohydrate antigen (CA) 242, thrombin time (TT), prothrombin time (PT), activated partial thromboplastin time (APTT), blood platelet count (PLT), white blood cell (WBC) count, C-reactive protein (CRP), neutrophil count (NC), lymphocyte count (LC), neutrophil-lymphocyte ratio (NLR), hemoglobin (HB), aspartate aminotransferase (AST), and ascites were found to have statistical differences between the two groups. Then, Stepwise Discriminant Analysis was conducted to establish a prediction model including 7 indexes (CA724, CA242, TT, PLT, CRP, AST, and ascites). According to the model, 90.6% of original grouped cases were correctly classified and 90.6% of cross-validated grouped cases were correctly classified.

We built a discriminant including CA724, CA242, TT, PLT, CRP, AST, and ascites for predicting patients with gastric cancer to be either stage IV or non-stage IV. According to this discriminant, 90.6% of patients could be correctly predicted.

1. Introduction

Gastric cancer is the second leading cause of cancer deaths worldwide despite a dramatic decline in its incidence over the past century [1]. Surgical resection of the primary tumor and regional lymph nodes is the only curative approach for gastric cancer. However, the overall prognosis remains poor and some cases are diagnosed as stage IV when seeing a doctor [2]. For patients with stage IV gastric cancer, surgery is not recommended except for patients with obstruction, perforation, or bleeding. So it is essential to assess the preoperative clinical stage to choose a proper treatment and avoid unnecessary surgery. At present, the assessment of the preoperative stage mainly relies on imaging examinations including computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography–computed tomography (PET-CT). However, imaging examinations could not make an accurate diagnosis when the metastatic lesion is too small or too hidden. Thus, the patients may suffer unnecessary surgery when imaging cannot discover metastatic lesions. So we need to explore a new method to predict stage IV gastric cancer to make up for the inadequacy of imaging.

Stage IV gastric cancer affects other systems and leads to a change of many indexes such as coagulation, inflammation, and nutrition. These serum biomarkers have the potential to act as supplementary tools for predicting the preoperative stage of gastric cancer. In this study, we analyzed retrospectively the preoperative indicators between stage IV and non-stage IV gastric cancer to investigate whether these indicators could predict the stage preoperatively.
2. Materials and Methods

2.1. Patients. The patients who had an accurate stage for gastric cancer at the Department of General Surgery, the Affiliated Hospital of Nanjing University Medical School, between January 2014 and December 2016 were analyzed retrospectively. Inclusion criteria are as follows: (1) patients with complete medical records; (2) patients without operation or chemoradiotherapy previously; and (3) non-stage IV patients with pathological diagnosis and stage IV patients with pathological or imaging diagnosis. Reasons for exclusion include accompanying other tumors, thrombosis and hemorrhagic disease, viscera function disorder, diabetes mellitus, and acute inflammation. Patients with bone marrow involvement are also excluded. The patients were divided into stage IV and non-stage IV groups. The diagnosis of gastric cancer with stage IV is as follows: (1) patients with metastases of other organs such as the liver, lung, and pancreas; (2) patients with peritoneal spread; and (3) patients with metastases of distant lymph nodes such as the supraclavicular lymph nodes. This study was approved by the IRB of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School. All methods were performed in accordance with the relevant guidelines and regulations. The written informed consents for participation in the study were obtained from all participants.

2.2. Analyzed Parameters. The parameters included in the analysis were categorized into clinical, imaging, and pathological data. The clinical indices included age, gender, tumor markers, coagulation function, inflammatory indices, nutritional status, and liver function. The imaging data was on whether the patient had ascites. The pathological data was mainly the TNM stage of gastric cancer. The pathological diagnosis was confirmed by at least two pathologists, and imaging diagnosis was also confirmed by at least two image doctors.

Tumor markers used in this analysis included alpha-fetoprotein (AFP), carcinoembryonic antigen (CEA), carbohydrate antigen (CA) 125, carbohydrate antigen (CA) 199, carbohydrate antigen (CA) 724, and carbohydrate antigen (CA) 242. These tumor markers were tested in the Nuclear Medicine Department through the tumor detection kit made by the Shanghai Biotechnology Co. Ltd. Coagulation function included activated partial thromboplastin time (APTT), prothrombin time (PT), thrombin time (TT), and blood platelet count (PLT). Inflammatory indices included white blood cell (WBC) count, neutrophil count (NC), lymphocyte count (LC), neutrophil-lymphocyte ratio (NLR), and C-reactive protein (CRP). Nutritional indices included hemoglobin (HB) and albumin (ALB). Liver enzyme parameters included alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), and direct bilirubin (DBIL). TNM staging was performed according to the American Joint Committee on Cancer Staging Manual (7th edition).

2.3. Statistical Analysis. A large number of variables (22 variables) were investigated in this study. For comparisons, the chi-squared test and two-tailed Student t-test were performed to identify factors related to stage. Then we used the Stepwise Discriminant Analysis (SDA) to establish a simple and useful prediction model based on the significant predictors. At last, we got the accuracy through cross validation. This method does not need another validation cohort to validate the effect of the models. Results were expressed as a hazard ratio (HR) with 95% CI. A p value of less than 0.05 was considered to be statistically significant. All tests were two sided. Data analysis was done with the SPSS Version 19.0 software.

3. Results

3.1. Sociodemographic Characteristics of the Patients. 500 patients were screened (354 men and 146 women, ages ranging from 21 to 92 years, with mean age 61.9 years). 470 patients were subjected to surgery. They were proved to be 128 cases of stage I, 101 cases of stage II, 172 cases of stage III, and 69 cases of stage IV gastric cancer. The remaining 30 cases were all diagnosed as stage IV by imaging examinations. The patients were divided into non-stage IV and stage IV groups. Stage I, stage II, and stage III were classified as the non-stage IV group. So there were 401 cases in the non-stage IV group and 99 cases in the stage IV group. Table 1 showed the distributions of the sociodemographic characteristics of the two groups. No statistically significant differences were observed on gender and age. The cases in both groups were comparable, with good proportionality.

3.2. Screening for the Predictors Related to Stage. 22 variables were analyzed in sequence, and the results are summarized in Table 1. We found that the following indexes had statistical differences between the two groups: AFP, CEA, CA125, CA199, CA724, CA242, TT, PT, APTT, PLT, WBC, CRP, NC, LC, NLR, HB, AST, and ascites.

3.3. Establishment of the Prediction Model. According to the screened 18 variables which were statistically significant, a prediction model of stage was conducted by a Stepwise Discriminant Analysis ($F_{\text{Entry}} = 3.84, F_{\text{Removal}} = 2.71$). The Stepwise Discriminant Analysis showed that Wilks lambda, as a test of the discriminant function, was significant (lambda = 0.506, chi-square = 318.809, df = 7, $p < 0.001$). 7 variables were selected as follows: CA724, CA242, TT, PLT, CRP, AST, and ascites (Table 2). Then Classification Function Coefficients are shown in Table 3. According to Table 3, we got the Bayesian discriminants: $F'(\text{non-stage IV}) = 15.468 \ast \text{ascites} - 0.001 \ast \text{CA724} + 9.366 \ast \text{TT} + 0.044 \ast \text{PLT} + 0.282 \ast \text{CRP} - 0.035 \ast \text{AST} - 97.274$. $F'(\text{stage IV}) = 25.678 \ast \text{ascites} - 0.001 \ast \text{CA724} + 9.091 \ast \text{TT} + 0.048 \ast \text{PLT} + 0.33 \ast \text{CRP} + 0.002 \ast \text{AST} - 108.563$. For a new patient, we put the values of these 7 indexes into the two discriminants and calculated the discriminant function value. If the $F'(\text{non-stage IV}) > F'(\text{stage IV})$, the subject was considered to be non-stage IV, and if the $F'(\text{non-stage IV}) < F'(\text{stage IV})$, the subject was regarded as stage IV. Complementarily, for patients
3.4. Predictive Effect Accuracy of the Prediction Model. The prediction of the accuracy of the prediction model was performed by cross validation (Table 4). The results showed that 90.6% of original grouped cases were correctly classified and 90.6% of cross-validated grouped cases were correctly classified.

| Table 1: Comparison of the clinical indexes between stage IV and non-stage IV groups. |
|-----------------|-----------------|-----------------|-----------------|
| Indexes         | Stage IV group  | Non-stage IV group | p value |
| Gender          |                 |                 |       |
| Male            | 63              | 291             | 0.085 |
| Female          | 36              | 110             |       |
| Age (yr)        | 61.29 ± 12.92   | 62.01 ± 11.24   | 0.802 |
| AFP (ng/mL)     | 8.06 ± 29.37    | 3.5 ± 6.95      | 0.006 |
| CEA (ng/mL)     | 130.50 ± 784.63 | 6.66 ± 36.10    | 0.002 |
| CA125 (U/mL)    | 42.45 ± 55.44   | 10.36 ± 8.33    | ≤ 0.001|
| CA199 (U/mL)    | 522.09 ± 2187.79| 43.35 ± 190.26  | ≤ 0.001|
| CA724 (U/mL)    | 372.37 ± 3129.16| 7.21 ± 42.39    | 0.022 |
| CA724 (U/mL)    | 473.32 ± 1925   | 31.30 ± 208.94  | ≤ 0.001|
| TT (s)          | 17.83 ± 1.57    | 18.38 ± 1.45    | 0.001 |
| PT (s)          | 12.23 ± 0.88    | 11.91 ± 1.21    | 0.015 |
| APTT (s)        | 29.77 ± 4.20    | 28.37 ± 4.00    | 0.002 |
| PLT (*10^9/L)   | 233.19 ± 99.08  | 208.22 ± 69.68  | 0.004 |
| WBC (*10^9/L)   | 60.0 ± 1.83     | 5.5 ± 1.52      | 0.005 |
| CRP (mg/L)      | 12.41 ± 18.75   | 4.38 ± 4.78     | ≤ 0.001|
| NC (*10^9/L)    | 3.9 ± 1.58      | 3.24 ± 1.15     | ≤ 0.001|
| LC (*10^9/L)    | 1.49 ± 0.56     | 1.73 ± 0.62     | 0.001 |
| NLR             | 3.10 ± 1.99     | 2.07 ± 1.05     | ≤ 0.001|
| HB (g/L)        | 113.45 ± 25.53  | 124.48 ± 25.53  | ≤ 0.001|
| ALB (g/L)       | 36.80 ± 4.05    | 39.18 ± 15.33   | 0.129 |
| ALT (U/L)       | 21.30 ± 28.90   | 18.19 ± 10.31   | 0.08 |
| AST (U/L)       | 24.89 ± 27.71   | 19.28 ± 6.98    | ≤ 0.001|
| TB (μmol/L)     | 10.63 ± 4.94    | 11.27 ± 5.45    | 0.289 |
| DB (μmol/L)     | 3.67 ± 1.97     | 3.55 ± 1.86     | 0.586 |
| Ascites         |                 |                 | ≤ 0.001|
| Yes             | 47              | 0               |       |
| No              | 52              | 401             |       |

without ascites, the value of ascites was 1, while, for patients with ascites, the value of ascites was 2.

4. Discussion

For patients with gastric cancer, preoperative tumor staging is useful to select the appropriate therapeutic strategy. Surgery is the main treatment measure for non-stage IV patients, while comprehensive therapy is proper for stage IV patients. So it is necessary to diagnose a patient as either stage IV or non-stage IV preoperatively. At present, the preoperative stage mainly relies on imaging examinations. However, imaging examinations easily lead to misdiagnosis or missed diagnosis when the metastatic lesion is too small or too hidden. Therefore, another method is needed to make up for the deficiency of imaging.

In the present study, we screened 7 indexes (CA724, CA242, TT, PLT, CRP, AST, and ascites) and got a discriminant for predicting stage. According to the cross validation, 90.6% of original grouped cases were correctly classified and 90.6% of cross-validated grouped cases were correctly classified. 90.6% of the original grouped cases were correctly classified. 90.6% of the cross-validated grouped cases were correctly classified.
Tumor markers are often measured for early detection and preoperative staging of gastric cancer. The commonly used markers are AFP, CEA, CA125, CA199, CA724, and CA242. Some studies have suggested their relevance to predict the preoperative stage. Cidon and Bustamante showed that the preoperative serum level of CA724 has the best predictive value in indicating advanced disease in patients diagnosed with gastric cancer [3]. Chen et al. found that CA724 was the most correlative serum tumor marker for gastric cancer [4]. Li et al. evaluated the correlation between tumor markers and the lymph node metastasis of gastric cancer and found that CA724 and CA242 were evaluated significantly in the gastric patients with later N stage [5]. Jing et al. found that CA724 and CA242 combined with other markers were a good evaluation indicator for gastric cancer [6]. Thus, CA724 and CA242 play an important role in predicting the preoperative stage.

Studies showed that the host inflammatory response to cancer cells is associated with tumor progression [7, 8]. Inflammation-associated proteins have been found to increase in malignancies. CRP is one of the inflammatory markers, which was found to be associated with poor prognosis in kinds of solid tumors [9–11]. Kong et al. found that high serum CRP level was associated with aggressive pathological features and was an independent poor prognostic factor for recurrent gastric cancer, which might be a potential prognostic marker for recurrent gastric cancer patients [12]. A study by Wang et al. suggests that CRP was directly related to the severity of the gastric cancer and a combination of some inflammatory serum proteins including CRP may serve as noninvasive markers to assess the severity status and stage of gastric cancer [13]. In this study, we found that CRP could contribute to predict the stage of gastric cancer and built an exact discriminant formula including CRP to predict the stage.

AST is a critical enzyme during the biological process. AST may increase in different hepatic injuries, such as hepatitis and cirrhosis induced by alcohol, drugs, viruses, and being under oxidative stress [14]. Oxidative stress and inflammation are associated with gastric cancer development, while oxidative stress and inflammation could also lead to the damage of liver cells. So AST may increase in gastric cancer. Reports have suggested that the presence of a systemic inflammatory response is linked to poor survival in patients with gastric cancer [15]. Therefore, AST could predict prognosis to some extent. Our study showed that the level of AST has significant difference between stage IV gastric cancer and non-stage IV and AST could help to predict the stage preoperatively.

Systemic hemostasis and thrombosis activation has been implicated in tumor progression and metastasis. The famous HYPERCAN study showed that hypercoagulation screening was an innovative tool for risk assessment, early diagnosis, and prognosis in cancer [16]. PLT and blood coagulation abnormalities occur frequently in gastric cancer. Some hematological parameters such as platelet have diagnostic power and can discriminate patients with gastric cancer from patients without cancer [17]. Thrombocytosis is considered an important risk factor, and it is associated with poor gastric cancer prognosis [18]. Chen et al. built the model "HALP" including PLT, which was closely associated with clinicopathological features and was an independent prognostic factor in gastric patients [19]. A series of studies showed that PLT could predict poor survival in patients with gastric cancer [20, 21]. Few researches showed that PLT and TT could take part in predicting the preoperative stage of gastric cancer. In our study, we found that PLT and TT could contribute to predicting stage.

For patients with advanced gastric cancer, preoperative examinations often revealed abnormal ascites, which could indicate the possibility of peritoneal metastasis. A Japanese research indicated that the presence of ascites was significantly correlated with peritoneal metastasis (p < 0.005), which was an independent prognostic factor. They concluded that the presence of ascites was strongly associated with peritoneal metastasis and might indicate the need for diagnostic laparoscopy to evaluate stage IV factors and select the best treatment strategy [22]. Pongpornsup et al. studied that peritoneal nodules, increased peritoneal fat density, ascites, and peritoneal thickening are ancillary signs suggestive of peritoneal carcinomatosis [23]. Repiso et al. also found that ascites are an important predictive factor of peritoneal carcinomatosis and may have significant implications in the management of patients with gastric cancer [24]. Similarly, there was a report that rapidly progressing ascites may be the sole presenting symptom of metastatic gastrointestinal carcinoma [25]. Besides, the survival of gastric cancer patients with ascites is relatively short, and the presence of ascites was an important prognostic factor [26]. Cheong et al. got a similar conclusion that the presence of ascites was closely associated with peritoneal metastasis and was the most significant independent prognostic factor in advanced gastric cancer [27]. Thus, ascites play an important role in predicting the stage and prognosis in gastric cancer. Our study showed that all patients with ascites were proved to be stage IV and ascites have a great effect in predicting the preoperative stage.

It is important to determine the stage preoperatively in order to choose the appropriate management of gastric cancer. The preoperative stage mainly relies on imaging examinations. Imaging examinations could not make a definite diagnosis when the metastatic lesion is too small or too hidden. So we need to explore new methods to make up for the inadequacy of imaging. However, there were few reports on this topic. Ohi et al. identified that a combination of specific factors is an alternative method to preoperatively discriminate patients with gastric cancer with peritoneal metastasis from those without [28]. This study focused on predicting peritoneal metastasis and on predicting patients with gastric cancer to be either stage IV or non-stage IV, which has more valuable clinical significance.

5. Conclusion

We built a discriminant including CA724, CA242, TT, PLT, CRP, AST, and ascites for predicting patients with gastric cancer to be either stage IV or non-stage IV. According to this discriminant, 90.6% of patients could be correctly
predicted. We will also carry out a prospective study to verify whether this discriminant could be used clinically.

**Ethical Approval**

This study was approved by the IRB of Nanjing Drum Tower Hospital, the Affiliated Hospital of Nanjing University Medical School. The written informed consents for participation in the study were obtained from all participants.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

Wei Ge participated in the study design, clinical data collection, and data analysis and wrote the paper. Li-ming Zheng participated in the clinical data collection and data analysis. Gang Chen conceived of the study, participated in its design, and gave final approval of the version to be published. All authors have read and approved the final paper.

**Acknowledgments**

The authors thank the patients for giving them written consent for publishing their details.

**References**

[1] M. Terry, M. Gaudet, and M. Gammon, "The epidemiology of gastric cancer," *Seminars in Radiation Oncology*, vol. 12, no. 2, pp. 111–127, 2002.

[2] H. Shimada, N. Takiguchi, O. Kainuma et al., "High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer," *Gastric Cancer*, vol. 13, no. 3, pp. 170–176, 2010.

[3] E. U. Cidon and R. Bustamante, "Gastric cancer: tumor markers as predictive factors for preoperative staging," *Journal of Gastrointestinal Cancer*, vol. 42, no. 3, pp. 127–130, 2011.

[4] X. Z. Chen, W. K. Zhang, K. Yang et al., "Correlation between serum CA724 and gastric cancer: multiple analyses based on Chinese population," *Molecular Biology Reports*, vol. 39, no. 9, pp. 9031–9039, 2012.

[5] F. Li, S. Li, L. Wei, X. Liang, H. Zhang, and J. Liu, "The correlation between pre-operative serum tumor markers and lymph node metastasis in gastric cancer patients undergoing curative treatment," *Biomarkers*, vol. 18, no. 7, pp. 632–637, 2013.

[6] J. X. Jing, Y. Wang, X. Q. Xu et al., "Tumor markers for diagnosis, monitoring of recurrence and prognosis in patients with upper gastrointestinal tract cancer," *Asian Pacific Journal of Cancer Prevention*, vol. 15, no. 23, pp. 10267–10272, 2014.

[7] L. M. Coussens and Z. Werb, "Inflammation and cancer," *Nature*, vol. 420, no. 6917, pp. 860–867, 2002.

[8] F. Balkwill and A. Mantovani, "Inflammation and cancer: back to Virchow?," *The Lancet*, vol. 357, no. 9255, pp. 539–545, 2001.

[9] K. Hashimoto, Y. Ikeda, D. Korenaga et al., "The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma," *Cancer*, vol. 103, no. 9, pp. 1856–1864, 2005.

[10] H. Shimada, Y. Nabeya, S. I. Okazumi et al., "Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma," *Journal of Surgical Oncology*, vol. 83, no. 4, pp. 248–252, 2003.

[11] J. E. M. Crozier, R. F. McKee, C. S. McCrindle et al., "Preoperative but not postoperative systemic inflammatory response correlates with survival in colorectal cancer," *British Journal of Surgery*, vol. 94, no. 8, pp. 1028–1032, 2007.

[12] F. Kong, F. Gao, J. Chen et al., "Elevated serum C-reactive protein level predicts a poor prognosis for recurrent gastric cancer," *Oncotarget*, vol. 7, no. 34, pp. 55765–55770, 2016.

[13] J. Wang, R. Ma, A. Sharma et al., "Inflammatory serum proteins are severely altered in metastatic gastric adenocarcinoma patients from the Chinese population," *PLoS One*, vol. 10, no. 4, article e0123985, 2015.

[14] M. Navarro, M. Montilla, A. Martín, J. Jiménez, and M. Utrilla, "Free radical scavenger and antihepatotoxic activity of Rosmarinus tomentosus," *Planta Medica*, vol. 59, no. 4, pp. 312–314, 1993.

[15] J. H. Park, D. G. Watt, C. S. D. Roxburgh, P. G. Horgan, and D. C. McMillan, "Colorectal cancer, systemic inflammation, and outcome: staging the tumor and staging the host," *Annals of Surgery*, vol. 263, no. 2, pp. 326–336, 2016.

[16] A. Falanga, A. Santoro, R. Labianca et al., "Hypercoagulation screening as an innovative tool for risk assessment, early diagnosis and prognosis in cancer: the HYPERCAN study," *Thrombosis Research*, vol. 140, Suppl 1, pp. S55–S59, 2016.

[17] L. Pietrzyk, Z. Plewa, M. Denisow-Pietrzyk, R. Zebrowski, and K. Torres, "Diagnostic power of blood parameters as screening markers in gastric cancer patients," *Asian Pacific Journal of Cancer Prevention*, vol. 17, no. 9, pp. 4433–4437, 2016.

[18] S. R. Park, J. S. Lee, C. G. Kim et al., "Endoscopic ultrasound and computed tomography in restaging and predicting prognosis after neoadjuvant chemotherapy in patients with locally advanced gastric cancer," *Cancer*, vol. 112, no. 11, pp. 2368–2376, 2008.

[19] X. L. Chen, L. Xue, W. Wang et al., "Prognostic significance of the combination of preoperative hemoglobin, albumin, lymphocyte and platelet in patients with gastric carcinoma: a retrospective cohort study," *Oncotarget*, vol. 6, no. 38, pp. 41370–41382, 2015.

[20] Z. Xin-Ji, L. Yong-Gang, S. Xiao-Jun, C. Xiao-Wu, Z. Dong, and Z. da-Jian, "The prognostic role of neutrophils to lymphocytes ratio and platelet count in gastric cancer: a meta-analysis," *International Journal of Surgery*, vol. 21, pp. 84–91, 2015.

[21] F. X. Li, L. J. Wei, H. Zhang, S. X. Li, and J. T. Liu, "Significance of thrombocytosis in clinicopathologic characteristics and prognosis of gastric cancer," *Asian Pacific Journal of Cancer Prevention*, vol. 15, no. 16, pp. 6511–6517, 2014.

[22] H. Matsuo, S. Komatsu, D. Ichikawa et al., "Clinical significance of ascites on preoperative MDCT in patients with advanced gastric cancer," *Gan to Kagaku Ryoho*, vol. 41, no. 12, pp. 2229–2231, 2014.

[23] S. Pongpornsup, P. Neungton, S. Chairoongruang, and P. Apisarnthanarak, "Diagnostic performance of multidetector computed tomography (MDCT) in evaluation for peritoneal metastasis in gastric cancer," *Journal of the Association of Thailand*, vol. 97, no. 8, pp. 863–869, 2014.

[24] A. Repiso, R. Lópe-Pardo, C. Arribas et al., "Significance of free periagaric fluid detected by echoendoscopy in patients
with gastric cancer, ” *Gastroenterología y Hepatología*, vol. 35, no. 10, pp. 691–696, 2012.

[25] M. Shimada, C. Berjohn, and D. A. Tanen, ”Ascites as the initial presentation of gastrointestinal carcinoma,” *The Journal of Emergency Medicine*, vol. 44, no. 2, pp. e195–e198, 2013.

[26] N. Fang, H. Q. Zhang, B. He et al., “Clinicopathological characteristics and prognosis of gastric cancer with malignant ascites,” *Tumour Biology*, vol. 35, no. 4, pp. 3261–3268, 2014.

[27] J. C. Cheong, W. H. Choi, D. J. Kim et al., ”Prognostic significance of computed tomography defined ascites in advanced gastric cancer,” *Journal of the Korean Surgical Society*, vol. 82, no. 4, pp. 219–226, 2012.

[28] M. Ohi, K. Mori, Y. Toiyama et al., ”Preoperative prediction of peritoneal metastasis in gastric cancer as an indicator for neoadjuvant treatment,” *Anticancer Research*, vol. 35, no. 6, pp. 3511–3518, 2015.